Lung Surgery With Enhanced Recovery VS. Lung Surgery Without Enhanced Recovery
Condition(s) studied
Investigational drug(s) / intervention(s)
Enhanced Recovery After Surgery (ERAS ): the treatment of procedure according to Guidelines for enhanced recovery after lung surgery: recommendations of the ERAS Society and the ESTS
Traditional perioperative management without Enhanced Recovery After Surgery (ERAS ): the treatment of procedure not abiding Guidelines for enhanced recovery after lung surgery
Study summary
Objective: The adoption of Enhanced Recovery Surgery programs in lung resection is relatively recent with limited outcome data. This study aimed to determine the impact of an Enhanced Recovery Surgery pathway on short- term and long- term results in patients undergoing lung resection for primary lung cancer.
Methods: A Randomized Controlled Trial was designed to collect the perioperative data on consecutive patients undergoing lung resection for primary lung cancer. Patients will be randomizely assigned to the ERAS- Group and Control- Group. Short-term and long- term effect will be compared between the two groups.
Eligibility
Primary outcome measure(s)
- intensive care unit utilization — within 4 days after surgery
the time in intensive care unit utilization - the degree of pain — within 4 days after surgery
Visual Analogue Scale/Score - the time of ambulation — within 48 hours after surgery
the time after surgery that patients could leave the bed and walk - the time for oral feed — within 48 hours after surgery
the time for oral feed - the time of hospitalization — within 5 days after surgery
the time of hospitalization - complications — within 7 days after surgery
the rate of complications
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Yunpeng Zhao | Jinan | Shandong | Recruiting |
More The Second Hospital of Shandong University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04451473 on ClinicalTrials.gov ↗ ← All trials in China